// App-Quantinova.ai

1018 : Structural features of novel dimeric quinacrines that have single-agent antitumor activity determine the mechanism of action: destabilization of mTORC1/lysosomal interaction versus DNA damage

Researchers

Presenter

  • Vito W. Rebecca

Principal Investigators

  • Michael Nicastri

  • Noel McGlaughlin

  • Quentin McAfee

  • Gao Zhang

  • Gretchen M. Alicea

  • Shengfu Piao

  • Colin Fennelly

  • Sengottuvelan Murugan

  • Zhi Wei

  • Gordon B. Mills

  • Yiling Lu

  • Meenhard Herlyn

  • Jeffrey D. Winkler

  • Ravi K. Amaravadi

Medical Centers

  • University of Pennsylvania, Philadelphia, PA

  • Wistar Institute, Philadelphia, PA

  • New Jersey Institute of Technology, Newark, NJ

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

  • Melanoma

  • Solid malignancies

Biomarkers

  • p70S6 kinase

  • Phosphorylated 4E-binding protein 1

  • KRAS proto-oncogene, GTPase

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Hydroxychloroquine

  • Gemcitabine

  • CBLC-102

  • Mefloquine

  • primaquine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved